OncoMatch/Clinical Trials/NCT07166419
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Is NCT07166419 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Autologous Anti-CD19/CD20/CD22 CAR T-cells and Cyclophosphamide for blast phase chronic myeloid leukemia, bcr-abl1 positive.
Treatment: Autologous Anti-CD19/CD20/CD22 CAR T-cells · Cyclophosphamide · Fludarabine — This phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as CD19, CD20 and CD22, on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving TriCAR19.20.22 T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory non-Hodgkin lymphoma, ALL and CLL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease
Required: CD20 overexpression
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease
Required: CD22 overexpression
The patient's lymphoid malignancy must be positive for CD19 and/or CD20 and/or CD22, either by immunohistochemistry or flow cytometry analysis on the last biopsy available or peripheral blood for circulating disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: Bruton's tyrosine kinase inhibitor — chronic lymphocytic leukemia
must have previously received an approved Bruton's tyrosine kinase (BTK) inhibitor
Must have received: BCL2 inhibitor (venetoclax) — chronic lymphocytic leukemia
must have previously received ... venetoclax
Must have received: tyrosine kinase inhibitor — chronic myeloid leukemia, lymphoid blast crisis
received at least 2 prior lines of therapy (tyrosine kinase inhibitors, multiagent chemotherapy)
Must have received: multiagent chemotherapy — chronic myeloid leukemia, lymphoid blast crisis
received at least 2 prior lines of therapy (tyrosine kinase inhibitors, multiagent chemotherapy)
Cannot have received: autologous stem cell transplant
Exception: relapse within 12 months of autologous stem cell transplant for refractory high-grade B-cell lymphoma
Autologous transplant within 6 weeks of planned CAR-T cell infusion
Cannot have received: allogeneic stem cell transplant
Allogeneic stem cell transplant or donor lymphocyte infusion within 2 months of planned CAR-T cell infusion and patients must be off immunosuppressive agents
Lab requirements
Blood counts
Absolute lymphocyte count ≥ 100/uL; if WBC is low and differential is not performed, CD3 count (helper/suppressor) should be ≥ 100/ul
Kidney function
Creatinine clearance ≥ 50 ml/min calculated by the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 times the institutional upper limit of normal; AST (SGOT) ≤ 3 x institutional upper limit of normal; ALT (SGPT) ≤ 3 x institutional upper limit of normal
Cardiac function
Left ventricular ejection fraction ≥ 40% in the most recent echocardiogram
Total bilirubin ≤ 1.5 times the institutional upper limit of normal; AST (SGOT) ≤ 3 x institutional upper limit of normal; ALT (SGPT) ≤ 3 x institutional upper limit of normal; Creatinine clearance ≥ 50 ml/min calculated by the Cockcroft-Gault formula; Absolute lymphocyte count ≥ 100/uL; if WBC is low and differential is not performed, CD3 count (helper/suppressor) should be ≥ 100/ul; Left ventricular ejection fraction ≥ 40% in the most recent echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07166419 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify